Biotech Stock Arcutis Climbs Into Buy Zone As FDA Mulls Expanded Use For Key Skin Treatment
Arcutis Biotherapeutics (ARQT) is currently in a buy zone and looks to stretch a winning streak, with the IBD 50 stocks To Watch pick for Thursday, and skin-disorders treatment specialist, appearing set to broaden its product reach and bolster sales. The biotech stock on Thursday was on course for a fourth consecutive gain. During the run, Arcutis secured regulatory acceptance…
Copyright ©2026 Investor's Business Daily, LLC. All rights reserved. 87990cbe856818d5eddac44c7b1cdeb8
Related news
Arcutis Biotherapeutics Shows Market Leadership With Jump To 82 RS Rating
3/25/2026 A Relative Strength Rating upgrade for Arcutis Biotherapeutics shows improving technical performance.
3/25/2026 A Relative Strength Rating upgrade for Arcutis Biotherapeutics shows improving...
Comments 0
Leave a Reply
Your email address will not be published. Required fields are marked *
Business & Finance
Explore AllAsk an Advisor: After a $40k Roth Conversion, Does the 5-Year Rule Still Apply?
Former Fed chair Ben Bernanke joins Anthropic's AI oversight trust
2 hours agoRetirees worry inflation will ravage their savings, but the reality is often less scary
2 hours ago
Biotech Stock Arcutis Climbs Into Buy Zone As FDA Mulls Expanded Use For Key Skin Treatment
2 hours agoPlume Brings Bitwise and Invesco RWA Yield to Binance Wallet
2 hours agoWhats New
View All
Call Of Duty: Black Ops 1 And 2 Ports Are Out Now On PS5, But DLC Costs Extra
FanDuel sent a video from star athlete Bryce Harper to a customer with a gambling problem
Mercor is in talks for a $20B valuation
Google will now disclose which ads are made with AI
These Celebrity-Adored, Very Large Sunglasses Are the Hottest Summer Accessory
Netflix Sets Golf Drama ‘Jupiter Island’ From ‘Love Story’ Creator and A24
Paris-based AI voice startup Gradium raises $100M seed, backed by Nvidia
Anthropic Wants You to Pay Up for Claude Fable 5
How did the government decide OpenAI’s frontier model was safe to release?
